MAPT and synucleinopathy: While recent advances in PET imaging and sensitive immunoassays of phosphorylated and total tau in plasma and CSF have improved the diagnosis of AD23, this is not yet true for tauopathies and synucleinopathies: PET tracers are still developing, and no reliable biomarker in plasma/CSF is ready to use in clinic for tauopathies.